US FDA approves Lilly's Mounjaro to reduce cardiovascular risk
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
🌍 Cross-language spread
This story first appeared in 🇪🇸 Spanish coverage — 4.7 hours before PULSE detected it in English news.
Detected by matching proper nouns and figures that survive translation. Times reflect when each edition's coverage was first indexed.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"US FDA approves Lilly's Mounjaro to reduce cardiovascular risk" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Bloomberg.com, Harvard Health, Fierce Pharma and Eli Lilly and Company. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 69d ago.
Quick answers
Why is "US FDA approves Lilly's Mounjaro to reduce cardiovascular risk" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (9)
- Mounjaro Is Now Approved to Lower the Risk of Heart Events Time Magazine · 69d ago
- Eli Lilly's diabetes drug Mounjaro gets approval for a new use USA Today · 69d ago
- Eli Lilly's diabetes drug wins FDA approval to lower heart attack and stroke risk qz.com · 69d ago
- Tirzepatide Gets FDA Approval to Cut Cardiovascular Risk in Type 2 Diabetes HCPLive · 69d ago
- Lilly Diabetes Shot Mounjaro Wins US Approval for Heart Disease Bloomberg.com · 69d ago
- Weight-loss drug may lower risk of heart attacks and infections Harvard Health · 69d ago
- Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients Fierce Pharma · 69d ago
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes Eli Lilly and Company · 69d ago
- US FDA approves Lilly's Mounjaro to reduce cardiovascular risk Reuters · 69d ago
Topics
Related trends
Exclusive | AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca has reportedly made a $10 billion bid to acquire Rhythm Pharmaceuticals, a specialist in obesity treatments.
Ultragenyx shrinks workforce and axes assets to halve R&D spend
Ultragenyx Pharmaceutical is slashing its workforce by 20% and reducing its real estate footprint to halve research and development spending.
Samsung's sleep apnea upgrade is rolling out to Galaxy Watch 9 and Galaxy Ring
6 news sources are covering this Technology story right now — PULSE is tracking how fast it spreads.
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027—Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical reports third-quarter 2026 results while announcing major workforce reductions and pipeline cuts to target profitability.
FDA elevates recall risk for blood pressure medication
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
FDA recalls thousands of blood pressure bottles, says pills failed quality tests
The FDA has initiated a nationwide recall of thousands of blood pressure medication bottles after pills failed quality tests.